Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.

Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet (2014) 6.52

A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med (2015) 4.79

PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. Science (1945) 4.05

Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A (1996) 3.54

Dengue. Lancet (2014) 2.53

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42

Phylogenetic relationships of dengue-2 viruses. Virology (1993) 2.16

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10

The human antibody response to dengue virus infection. Viruses (2011) 1.79

Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J Virol (1995) 1.60

Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol (2005) 1.56

Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol (2002) 1.47

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis (1996) 1.45

Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine (2013) 1.34

Dengue vaccines approach the finish line. Clin Infect Dis (2007) 1.32

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol (2000) 1.18

Current progress in dengue vaccines. J Biomed Sci (2013) 1.16

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg (2003) 1.15

Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis (2012) 1.14

Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res (2001) 1.11

Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol (2011) 1.05

A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol (2012) 0.95

Outlook for a dengue vaccine. Clin Microbiol Infect (2014) 0.86

Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology (2012) 0.86

[Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program]. Salud Publica Mex (2016) 0.86